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LYME DISEASE:
OF DELEGATES

THE SURPRISING DEBATE IN THE 2010 VIRGINIA HOUSE

Gerald C. Canaan,11* & Karah L. Gunther**

In most every General Assembly session, there are those bills thatwhile on the surface appear fairly innocuous-quickly take on a life of their
own, generating an audible buzz in and around the General Assembly
Building. The 2010 Virginia General Assembly session was no different.
Amidst hallway discussions concerning the budget, gun rights, and

abortion, one could also hear the distinct murmur of a completely novel
topic: Lyme disease. Often associated with a small, pesky insect known as
the black-legged tick,1 until this year, Lyme disease had not been the
subject of any controversial legislation proposed in the Commonwealth of
Virginia, until this year. 2 In 2010, five separate bills pertaining to Lyme
disease were proposed, primarily by elected representatives from the
Northern Virginia area, allowing the unwelcome summer guest to achieve a
newfound level of notoriety. 3 And one thing remains sure: the tick's recent
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1. VA. DEP'T OF HEALTH, PREVENTING TICK-BORNE DISEASES IN VIRGINIA (August 2008),
http://www.vdh.virginia.gov/epidemiology/DEE/Vectorborne/documents/Ticko20Brochure-8%o 2 0 5x 1I
.pdf.
2. See Legislative Information System, Bill Tracking,
http://legsearch.state.va.us/search?q=lyme+disease&Search=search&site=LIS&clientLIS&outputrxml
no dtd&proxystylesheet-LIS&filter=O (last visited Mar. 5, 2010) (showing that Lyme disease has not
been the topic of controversial legislation in the Commonwealth of Virginia beyond legislation passed in
1999 to require a study examining issues relating to the incidence, reporting, treatment, and prevention
of Lyme disease in Virginia, and proposed legislation that failed to become law in 2007 regarding
reporting requirements).
3. See H.B. 36,2010 Gen. Assem., Reg. Sess. (Va. 2010); H.B. 512, Gen. Assem., Reg. Sess. (Va.
2010); H.B. 897, Gen. Assem., Reg. Sess. (Va. 2010); H.B. 1017, Gen. Assem., Reg. Sess. (Va. 2010);
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rise to fame will not be short-lived; Lyme disease will continue to be a
contested issue in the legislative sessions ahead.
BACKGROUND

A. What is Lyme Disease?
Lyme disease in humans is caused by infection with a spiral-shaped

bacterium called Borrelia burgdorferi.4 The bacteria are carried and
transmitted to humans by the black-legged tick (formerly known as the deer
tick). 5 Indeed, the black-legged tick is the only known carrier of the disease
in the Eastern United States. 6 Transmission of the disease typically occurs
in the late spring and early summer when young, or nymph stage ticks, are
active and feeding. 7 Tick nymphs themselves become infected with the
bacteria after feeding on certain rodent species. 8
Transmission of the disease does not usually occur until the tick has
been attached and feeding on the human host for approximately 36 hours. 9
In as little as a few days or as long as a few weeks following the infectious
tick bite, many patients (approximately 80 percent) will develop a red rash
called an erythema migrans, or "bull's eye" rash, which slowly expands and
clears around the center of the bite site.10 Other more immediate symptoms
can include fatigue, general malaise, fever, headache, stiff neck, muscle
aches, and joint pains.11 However, if left untreated, some patients can
develop longer-term symptoms, including arthritis, neurological problems,
and/or heart problems. 12 Unfortunately, since black-legged ticks are small,
often difficult to see, and generally cause no itch or irritation at the site of
the bite, many people are not aware that they have been bitten. 13 Thus, the
disease can go unnoticed for quite some time.
The prevalence of Lyme disease has risen significantly in the United
States, particularly on the East Coast. Although it is unclear whether
and H.B. 1288, Gen. Assem., Reg. Sess. (Va. 2010).
4. VA. DEP'T OF HEALTH, supra note 1.
5. Id.
6. Id.
7. Id.
8. Id.
9. Id.
10. VA. DEP'T OF HEALTH, LYME DISEASE (Updated Mar. 3, 2009),

http://www.vdh.virginia.gov/epidemiology/DEE/Vectorbome/factsheets/pdf/lyme.pdf11. Id.
12. Id.
13. VA. DEP'T OF HEALTH, supra note 1.
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increases are due to heightened recognition and education, or whether they
are due to an actual jump in the incidence of the disease, the number of
confirmed reported cases in the United States in 2008 was 28,921.14 This is
an increase from 19,804 cases in 2004 and 16,273 cases in 1999.15 In
Virginia alone, there were 886 confirmed cases reported to the Centers for
Disease Control. 16 Most of these cases were reported in Northern Virginia,
which is comprised of once heavily wooded areas that are now becoming
more densely populated due to the urban sprawl surrounding Washington,
D.C.. Loudon County, just west of Washington, D.C. reports having an
incidence rate nearly twenty times greater than that of the Virginia
average. 17
B. "Two Schools of Thought"
The next question that logically follows is: how is Lyme disease
treated? This question, and its variant answers, comprise the larger part of
the Lyme disease debate in the 2010 General Assembly. Over the past
several years, two separate "factions" have emerged, and each has its own
view regarding how Lyme disease should be treated. First, there are the
"mainstream" physicians who, along with the Centers for Disease Control
and Prevention (CDC), National Institutes of Health (NIH), Infectious
Diseases Society of America (IDSA), and the American Academy of
Neurology (AAN), feel that most instances of Lyme disease can be cured
with a few weeks of taking oral antibiotics. 18 This group generally
concedes that in a relatively smaller number of cases, patients with
persistent or recurrent symptoms may require a second four-week course of
therapy. 19 Any antibiotic treatment beyond this, however, is not seen to be
beneficial and is believed to result in serious complications, including the

14. CENTERS FOR DISEASE CONTROL, DIVISION OF VECTOR-BORNE INFECTIOUS DISEASES, REPORTED
LYME DISEASE CASES BY STATE, 1999-2008 (August 2009),

http://www.cdc.gov/ncidod/dvbid/lyme/resources/ReportedCasesLymeDisease99-2008.pdf.
15. Id.
16. Id.
17. Loudon
County
Government,
Lyme
Disease/Tick-borne
http://www.loudoun.gov/Default.aspx?tabid=726 (last visited Mar. 5, 2010).

Diseases,

18. AMERICAN ACADEMY OF NEUROLOGY, EVIDENCE BASED GUIDELINES, TREATMENT OF NERVOUS
SYSTEM LYME DISEASE, http://www.aan.com/practice/guideline/uploads/243.pdf (last visited Mar. 5,

2010); Centers for Disease Control, Division of Vector-Borne Infectious Disease, Lyme Disease
Treatment and Prognosis, http://www.cdc.gov/ncidod/dvbid/lymeld humandisease treatment.htm (last
visited Mar. 5, 2010); Infectious Diseases Society of America, Frequently Asked Questions About Lyme
Disease, http://www.idsociety.org/lymediseasefacts.htm (last visited Mar. 5, 2010); National Institutes
of Health, National Institute of Allergy and Infectious Diseases, Understanding Lyme Disease: Chronic
Lyme Disease, http://www3.niaid.nih.gov/topicslymeDisease/understanding/chronic.htm (last visited
Mar. 5,2010).
19. Infectious Diseases Society of America, supranote 18.
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elimination of "good" bacteria from the immune system, secondary
infections that are passed through intravenous lines used to administer the
antibiotics, adverse reactions to the drugs themselves, and overall
antimicrobial resistance. 20 The mainstream group tends to doubt the
existence of "chronic Lyme disease," which has been used to describe some
patients who exhibit symptoms of Lyme (such as fatigue and painsymptoms commonly experienced in the rest of the population), but who
21
have never actually tested positive for the bacteria.
On the other hand, there are those who fiercely advocate for longterm antibiotic treatment, which can last for months or even years. This
group, comprised of patient advocates and those physicians they consider to
be forward-thinking (often referred to and identified as "Lyme-literate
22
medical doctors"), has become increasingly vocal over the past few years.
Both the patients and the doctors who comprise this side of the debate voice
frustration with standard treatments, and they believe that many diffuse
ailments, from arthritis and headaches to irritability and poor concentration,
are actually symptoms of lingering, active Lyme disease. 23 Specifically,
they believe that an ongoing infection with the spirochetal bacterium
Borrelia burgdorferi may be the cause of persistent symptoms in chronic
Lyme disease. 24 Thus, extended courses of antibiotics are seen as the only
way to provide meaningful symptomatic relief in chronic patients. 25 The
"very real consequences" of untreated persistent Lyme infection are
perceived to far outweigh the potential adverse side effects of long-term
26
antibiotic therapy.
Lyme activists, whose national lobbying arms include the Lyme Disease
Association and the International Lyme and Associated Diseases Society
(ILADS), 27 have attacked legislation on state and federal levels, protested

outside doctors' offices, and lined up powerful allies, including the
Connecticut Attorney General. 28 One of the Lyme activists' strongest
20. Centers for Disease Control, supra note 14, National Institutes of Health, supra note 18 (emphasis
added).
21. Id.
22. Jason Feifer, Combat Zone: There's No Neutral Ground in War of Information About Lyme
Disease, WASH. POST, May 15, 2007.
23. Id.
24. Id.
25. International Lyme and Associated Diseases Society, ILADS Lyme Disease Treatment Guidelines
Summary, http://www.ilads.org/lyme disease/treatment guidelines summary.html (last visited Mar. 4,
2010).
26. Id.
27. See International Lyme and Associated Diseases Society, http://www.ilads.org/ (last visited Mar. 5,
2010); Lyme Disease Association, Inc., http://www.lymediseaseassociation.org/ (last visited Mar. 5,
2010).
28. Feifer, supranote 22.
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fights to date has been to challenge the IDSA-developed guidelines for the
treatment of Lyme disease. 29 The IDSA guidelines, which are considered
to be the "prevailing" or majority view state, "[a]ntibiotic therapy has not
proven to be useful and is not recommended for patients with chronic (> 6
months) subjective symptoms after recommended treatment regimens for
Lyme disease ....
,,30
The guidelines further advise against other
therapeutic modalities, including, but not limited to, "pulsed-dosing (i.e.,
dosing on some days but not others)," hyperbaric oxygen, fever therapy,
intravenous immunoglobulin, and specific nutritional supplements. 31 Lyme
advocates have vehemently opposed these guidelines, claiming that they are
"one-sided" and prevent otherwise qualified doctors from recognizing and
treating the symptoms of "chronic Lyme. ' 32 After the promulgation of the
IDSA guidelines in 2006, Lyme advocates appealed to the Connecticut
Attorney General to investigate what they perceived to be an inherent
unfairness in the guidelines. 33 In response, the Attorney General's antitrust
division conducted an in-depth analysis of the IDSA guidelines, searching
for conflicts of interest among panelists and looking for the exclusion of
differing, yet legitimate points of view. 34 Ultimately, the IDSA voluntarily
agreed to a one-time special review of its guidelines, with the proviso that
the current guidelines would stay intact until a comprehensive review panel
holds that they should be revised. 35 The results of this review have not yet
been published. In the meantime, Lyme activist groups have proactively
developed their own guidelines for treatment of the disease. 36 The ILADS
guidelines specifically address the fact that treatment should not be

withheld solely based on laboratory testing, and they also recommend both
longer courses of antibiotic treatment, as well as repeat antibiotics for
37
recurrence.

29. Id.
30. Gary P. Wormser et al., The Clinical Assessment, Treatment, and Prevention of Lyme Disease,
Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious
DiseasesSociety ofAmerica, 43 CLINICAL INFECTIOUS DISEASES 1089, 1094 (2006).

31. Id.
32. Feifer, supranote 22.
33. Id.
34. Press Release, Conn. Attorney Gen.'s Office, Attorney General's Investigation Reveals Flawed
Lyme Disease Guideline Process, IDSA Agrees To Reassess Guidelines, Install Independent Arbiter
(May 1, 2008), http://www.ct.gov/AG/cwp/view.asp?a=2795&q=414284 (last visited Mar. 5, 2010).
35. Press Release, Infectious Diseases Society of America, Agreement Ends Lyme Disease
Investigation by Connecticut Attorney General: Medical Validity of IDSA Guidelines Not Challenged,
https://www.idsociety.org/Content.aspx?id=l 1182 (last visited Mar. 4, 2010).
36. ILADS Lyme Disease Treatment Guidelines Summary, supranote 25.
37. Id.
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Beyond challenging the traditional schools of thought, Lyme activists
have exercised their political clout to successfully enact legislation in
several states that will protect physicians who prescribe extended courses of
antibiotics. In 2009, at the urging of vocal patient advocates, the
Connecticut General Assembly passed a bill containing language that
protects licensed physicians from disciplinary action by the State of
Connecticut Medical Examining Board solely on the basis of a clinical
diagnosis and/or treatment of chronic Lyme disease. 38 Specifically, a
Connecticut statute now provides that a "physician may prescribe,
administer, or dispense long-term antibiotic therapy" to Lyme patients,
provided the physician clearly documents a clinical diagnosis and treatment
plan in the patient's medical record. 39 Rhode Island passed similar
legislation, where in addition to protecting doctors from medical board
investigation, the law further provides that insurance companies must
40
provide coverage for Lyme disease treatment.
Local Lyme advocacy groups have taken note of these recent successes
and have quickly begun to expand legislative efforts in their home states.
Bills that extend protection to Lyme literate doctors who prescribe longterm antibiotics are being proposed across the country. 41 In Virginia, a

highly organized advocacy group, known as the National Capital Lyme &
Tick-Borne Disease Association ("NatCapLyme"), played a critical role in
42
gaining support and patronage for five Lyme disease-related bills.
2010 PROPOSED VIRGINIA LEGISLATION & OUTCOMES
Of the five bills proposed this legislative session regarding Lyme
disease, all but one were incorporated into Delegate Tom Rust's House Bill
512. 43 Specifically, House Bill 897 (sponsored by Delegate Barbara
Comstock), House Bill 1017 (sponsored by Delegate Tim Hugo), and

38. H.B. 6200, Conn. Gen. Assembly (Reg. Sess. 2009) (enacted as Act of July 1, 2009, 2009 Conn.
Acts 09-128) (codified as state law at CONN. GEN. STAT. § 20-14m (2010)).
39. Id.
40. R.I. GEN. LAWS §5-37.5-4(a) (2009)(stating that "[n]o physician is subject to disciplinary action by
the board solely for prescribing, administering, or dispensing long-term antibiotic therapy for a
therapeutic purpose for a patient clinically diagnosed with Lyme disease..."); R.I. GEN. LAWS §5-37.5-5
(2010).
41. See Lymelnfo.net, Past Lyme Disease Advocacy Events,
http://www.lymeinfo.net/advocacyevents.html (last visited Mar. 30, 2010).
42. See National Capital Lyme & Tick-Borne Disease Association,
http://www.natcaplyme.org/index.php (last visited March 8, 2010); infra Part II.
43. H.B. 36, Gen. Assem., Reg. Sess. (Va. 2010); H.B. 1288, Gen. Assem., Reg. Sess. (Va. 2010); H.B.
512, Gen. Assem., Reg. Sess. (Va. 2010); H.B. 897, Gen. Assem., Reg. Sess. (Va. 2010); H.B. 1017,
Gen. Assem., Reg. Sess. (Va. 2010).
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House Bill 1288 (sponsored by Delegate Ken Plum) were all incorporated
into Delegate Tom Rust's House Bill 512. 44 Notably, all of the chief
patrons, as well as a significant number of the co-patrons, represent districts
in Northern Virginia, where the prevalence of Lyme disease is reported to
be quite high.45 Delegate Rust's bill addressed long-term prescribing of
antibiotics for patients with chronic Lyme disease, largely mirroring the
language of the Connecticut and Rhode Island legislation. 46 In particular,
the bill sought to clarify that "[a] licensed physician may prescribe,
administer, or dispense long-term antibiotic therapy to a [Lyme disease]
patient... , provided such clinical diagnosis and treatment are documented
in the patient's medical record by such licensed physician. ' 47 Similar to
legislation proposed in other states, the bill also sought to prohibit the
Virginia Board of Medicine from bringing disciplinary action against
physicians solely for prescribing, administering, or dispensing long-term
48
antibiotic therapy to Lyme patients.
The House of Delegates Health, Welfare and Institutions
Subcommittee meeting 49 at which the incorporated bill was heard, drew a
large crowd that mostly comprised of Lyme disease patients, their families,
and physician advocates. However, also on hand were members of the
Virginia medical community, who primarily attended to oppose the bill.
Both sides were given a limited amount of time to advance their respective
arguments for or against the bill. Among those who provided testimony in
support of the bill were several Lyme disease patients, a physician advocate
from Northern Virginia, and the legal counsel to NatCapLyme.
Additionally, a letter was read that was written by a physician who herself

44. See Legislative Information System, Bill Tracking: H.B. 897, 2010 Session,
http://legl.state.va.us/cgi-binlegp5O4.exe?ses=101&typ=bil&val=hb897 (last visited Mar. 30, 2010);
Legislative Information System, Bill Tracking; H.B. 1017, 2010 Session, http://legl.state.va.us/cgibin/legp504.exe?ses = 101&typ=bil&val=hbI17 (last visited Mar. 30, 2010); Legislative Information
System, Bill Tracking, H.B. 1288, 2010 Session,
http://legl.state.va.us/cgi-in/legp504.exe?ses=101&typ=bil&val=hb1288 (last visited Mar. 30, 2010);
Legislative Information System, Bill Tracking, H.B. 512, 2010 Session, http://legl.state.va.us/cgibin/legp504.exe?ses=101&typ=bil&val=hb512 (last visited Mar. 30, 2010) (hereinafter "Bill Tracking
H.B. 512"); Legislative Information System, H.B. 36, 2010 Session, http://legl.state.va.us/cgibin/legp504.exe?ses=101&typ=bil&val=hb36 (last visited Mar. 30, 2010) (hereinafter "Bill Tracking
H.B. 36").
45. See
Legislative
Information
System,
Bill
Tracking:
Members,
2010
Session,
http://legl.state.va.us/101/mbr/MBR.HTM (last visited Mar. 30, 2010) (hereinafter "Bill Tracking
Members"); supranotes 16-17 and accompanying text.
46. See H.B. 512, Gen. Assem., Reg. Sess. (Va. 2010), 1, § 54.1-3408.2 (as introduced Jan. 13,
20010); supranotes 38 and 40 and accompanying text.
47. H.B. 512,

1, § 54.1-3408.2(A).

48. Id.
49. The discussion that follows is based on personal attendance at the first House of Delegates Health,
Welfare, and Institutions Subcommittee meeting that was held in the Virginia General Assembly
building on February 1, 2010 at 5:00 p.m.
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suffers from Lyme disease and who advocates protection of those doctors
who choose to prescribe long-term antibiotics. The advocates' testimony,
often quite emotional, urged legislators to take notice of the growing
prevalence of Lyme disease in our state and also urged them to consider the
possibility that there may be more than one "right" way to treat chronic
symptoms of Lyme disease.
In rebuttal, the Medical Society of Virginia ("Medical Society") took
the stance that extended courses of antibiotics are often inappropriate,
particularly when there is no laboratory evidence that the patient was ever
infected with the bacteria. Two physicians speaking on behalf of the
Medical Society, one of whom was the former president of the IDSA,
pointed out the harms that can occur when a person stays on antibiotics for
too long, including bloodstream infections caused by intravenous
administration and the creation of "superbugs" that can become resistant to
antibiotic treatment. The Medical Society also expressed concern that
passing the legislation would be akin to codifying a standard of care,
something physicians have traditionally cautioned against. Physicians have
long advocated that whenever the legislature attempts to dictate the standard
of care, it is a slippery slope whereby state legislators can begin dictating
courses of care for other medical conditions. Particularly in this case, the
Medical Society argued it would be dangerous to legislate a standard of care
that was indeed a controversial one and over which the medical community
was divided. Further, while House Bill 512 would not specifically mandate
that a physician choose long-term antibiotic therapy for patients who
exhibit chronic, Lyme-like symptoms, the legislation's permissive choice
could open the door to challenging a physician's clinical determination to
not use long-term therapy. Finally, citing anecdotal information provided
by the Virginia Department of Health Professions, the Medical Society
explained that physician investigations by the Board of Medicine were not
an issue in the Commonwealth. According to the Department of Health
Professions, only one physician had ever been investigated for improperly
prescribing antibiotics to a Lyme disease patient, and that complaint had
subsequently been dropped.

Ultimately, the House Subcommittee chose to carry the bill over to
the 2011 regular session.5" There was only one dissenting vote to the
Subcommittee's recommendation to carry the bill over, and Delegate Lionel
Spruill of the 77th District voiced that dissent. 51 Delegate Spruill indicated
50. See Bill Tracking: H.B. 512, supra note 44 (stating that the "[s]ubcommittee recommends
continuing to 2011 by voice vote.").
51. See Bill Tracking: Members, supra note 44.
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his concern for failing to take action on the bill during the 2010 session,
pointing to the large number of advocates who had traveled considerable
distances to make their opinions known. In explaining the Subcommittee's
decision to carry the bill over to the next session, the chair of the
subcommittee, Delegate John O'Bannon (himself a physician), gave the
stakeholders a verbal command to begin working with one another towards
a resolution during the interim. The Virginia Department of Health,
represented by Commissioner Dr. Karen Remley, agreed to draft a letter to
all physicians in the Commonwealth and underscore the increasing
prevalence of Lyme disease in the state. The following day, the full House
Committee of Health, Welfare, and Institutions affirmed the
subcommittee's recommendation to carry the bill over by a voice vote. 52
The one remaining bill that was not incorporated in House Bill 512,
and was thus heard alone by the House Health, Welfare and Institutions
Subcommittee meeting, was House Bill 36, sponsored by Delegate Robert
G. Marshall of the 13th District. 53 Delegate Marshall's bill sought to
require that Lyme disease be included among the Virginia Board of
Health's list of reportable diseases. 54 The Medical Society opposed this bill
as well, arguing that House Bill 36 was duplicative of already existing law.
Specifically, the Medical Society pointed out in oral testimony that
Delegate Marshall's proposed statutory requirement was unnecessary, since
the Health Board's regulations already require that certain health care
providers report Lyme disease to specified health agencies. 55 The
Subcommittee ultimately agreed with this conclusion and recommended
56
tabling the bill by a voice vote.
FUTURE OUTLOOK

Although no immediate action was taken on House Bill 512 in the
2010 session, the fact that the bill has been carried over to the 2011 session
signals that this issue is far from over. Large numbers of patient advocates
(or in other words, large numbers of voting constituents) have made their
opinions known, and legislators have taken note. Even after House Bill 512
was carried over in the Commonwealth of Virginia, the issue did not
immediately fall off the General Assembly members' radars. A newly
formed joint caucus of the House and Senate known as the "Allied Health
52. Bill Tracking: H.B. 512, supra note 44 (stating that House Bill 512 was "[c]ontinued to 2011 in
Health, Welfare, and Institutions by voice vote.").
53. See supra notes 43-44 and accompanying text.
54. H.B. 36, Gen. Assem., Reg. Sess. (Va. 2010), 1, § 32.1-35 (as introduced Jan. 13, 2010).
55. See 12 VA. ADMrN. CODE §5-90-80, which includes "Lyme disease" as a reportable disease.
56. Bill Tracking: H.B. 36, supra note 44.
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Caucus" held its first meeting in February on the subject of Lyme disease.
Dr. Keri Hall, Director of Epidemiology in the Commonwealth of Virginia,
provided up-to-date statistics on the prevalence of Lyme disease in Virginia
and helped explain the current state of scientific research from a nonpoliticized standpoint.
Legislators responded with many questions,
signaling their ongoing desire to learn more about this complex and often
highly divisive topic.
Lyme advocacy groups continue to work tirelessly in surrounding
states as well. At the time of this submission, there is currently an ongoing
57
debate over proposed Lyme disease legislation in the state of Maryland.
Interestingly, it seems that at least some members of the Lyme community
are in fact opposed to legislation that purports to extend immunity to
physicians who prescribe long-term antibiotics, claiming that the bill does
not go far enough to provide Lyme literate medical doctors with the
protection that they need. 8 The Maryland bill provides that physicians
may prescribe long-term antibiotics to treat Lyme disease, so long as the
Centers for Disease Control do not publish additional guidance that would
recommend against this form of therapy. 59 Lyme advocates also take issue
with the fact that the Maryland bill defines Lyme disease as an "acute"
infection with Borrelia burgdorferi and that it allows the State Medical
Board to investigate a physician for prescribing the incorrect long-term
60
antibiotic.
As the debate in Maryland illustrates, Lyme advocates are not likely
to bend easily. They will continue to fight for unfettered access to longterm antibiotic therapy, and they will continue to ensure that both state and
national lawmakers alike hear their voices. While organized medicine will
likely continue to insist on a reliable amount of evidence-based research
before lending its support to long-term therapy, health care providers would
be remiss to ignore the issue. Given Chairman O'Bannon's charge during
the bill hearing, all stakeholders must be prepared to work together this
coming summer. The Medical Society, along with the relevant state health
agencies, must stand ready to further educate both physicians and the
Virginia citizenry at large about the increasing prevalence of Lyme disease.
For, just as sure as humidity and warmer temperatures will begin to descend
on our great Commonwealth, so too will the "tick." But this time, he may
extend his stay - at least figuratively - through February or March.

57. H.B. 290, Md. Gen. Assem. (Reg. Sess. 2010), 1, § 14-508 (as introduced Jan. 27, 2010).
58. Posting
of
Bettyg
to
MDJunction.com,
Lyme
Disease
Support
Group,
http://www.mdjunction.com/forums/lyme-disease-support-forums/yme-disease-activism/1221662maryland-bill-submitted-bad-bill-alert-2610 (Feb. 6, 2010, 1:40 EST (hereinafter "Posting of Bettyg")).
59. H.B. 290, supranote 57.
60. Posting of Bettyg, supranote 58 (citing H.B. 290, 1, § 14-508(A)(4) and (E)(4)).

